Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based...

Area of Science:

• Pharmacovigilance
• Gastroenterology
• Clinical Epidemiology

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
• Upper gastrointestinal bleeding is a significant clinical concern with various contributing factors.

Purpose of the Study:

• To investigate the association between SSRI use and the risk of upper gastrointestinal bleeding.
• To evaluate the impact of concurrent use of SSRIs with other medications on this risk.

Main Methods:

• A population-based case-control study was conducted using data from UK general practices.
• 1651 cases of upper gastrointestinal bleeding and 10,000 controls were analyzed.
• Exposure to SSRIs and other antidepressants within 30 days of the index date was assessed.

Main Results:

• Current SSRI use was associated with a 3-fold increased risk of upper gastrointestinal bleeding (adjusted rate ratio 3.0).
• This risk was not significantly modified by patient demographics, SSRI dose, or duration of treatment.
• Concurrent use of SSRIs with non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin substantially increased the risk of gastrointestinal bleeding.

Conclusions:

• SSRIs are linked to a moderate increase in upper gastrointestinal bleeding risk.
• The risk is significantly amplified when SSRIs are co-prescribed with NSAIDs or aspirin.
• Clinicians should exercise caution when prescribing SSRIs, particularly in patients also taking NSAIDs or aspirin.